Indapamide Tab n / a film about 2.5 mg 30 pcs


Indapamide Tab n / a film about 2.5 mg 30 pcs

5 in stock


SKU: 01773648138 Categories: , , Tags: ,


Active substance:
1 tablet contains: 2.5 mg indapamide ;.
Product form:
Tablets, film-coated 2.5 mg.
Hypersensitivity to indapamide, other derivatives of the sulfonamide or other components of the formulation; severe renal failure (creatinine clearance (CC) of less than 30 ml / min); hepatic encephalopathy or severe hepatic failure; hypokalemia; lactose intolerance, lactase deficiency or glucose-galaktaznaya malabsorption; age 18 years (effectiveness and safety have been established); pregnancy; during breastfeeding.
Disturbances of liver and / or kidney (CK more than 30 ml / min), diabetes mellitus, old age, disorders of fluid and electrolyte balance, hyperuricemia (especially accompanied urate gout and nephrolithiasis), hyperparathyroidism; patients with extended intervals QT on ECG or receiving therapy, resulting in possible lengthening of the interval QT (astemizole, erythromycin (i.v.), pentamidine, sultopride, terfenadine, vincamine, antiarrhythmic drugs IA class (quinidine, disopyramide) and III-class (amiodarone, bretylium tosylate)).
2.5 mg
Arterial hypertension.
Interaction with other drugs
While the use of drugs lithium, indapamide increases the concentration of lithium ions in the plasma (by reducing its renal excretion).
When used simultaneously with the iodine-containing contrast media with high doses indapamide increases the risk of kidney function disturbances (by reducing the circulating blood volume (CBV)). Before using iodinated contrast agents to patients is necessary to make correction BCC.
Indapamide reduces the effect of anticoagulants (coumarin or indandione derivatives) by increasing the concentration of coagulation factors (by reducing the bcc).
Indapamide increases the effects of non-depolarizing muscle relaxants.
The risk of developing hypokalemia increases while the use of indapamide with diuretics ( “loop” thiazide), cardiac glycosides, glucocorticosteroids, mineralocorticoids, tetrakozaktidom, amphotericin B (i.v.), laxatives.
At the same time taking indapamide with cardiac glycosides increases the likelihood of digitalis intoxication; with calcium supplementation – hypercalcemia; metformin – worsening lactic acidosis.
Astemizole, erythromycin (i.v.), pentamidine, sultopride, terfenadine, vincamine, antiarrhythmic drugs of class IA (quinidine, disopyramide), and Class III (amiodarone, bretylium tosylate) can increase the risk of arrhythmia type “pirouette” by lengthening the interval QT.
Nonsteroidal anti-inflammatory drugs, glucocorticoids, tetracosactide, adrenostimulyatorov reduced hypotensive effect indapamide, baclofen – increases.
Angiotensin converting enzyme while the use of indapamide increased risk of developing orthostatic hypotension and / or acute renal failure (especially in the presence of renal artery stenosis).
Imipraminovye (tricyclic) antidepressants and antipsychotic drugs (neuroleptics) increase the hypotensive action of indapamide and increase the risk of orthostatic hypotension. Cyclosporin increases the risk of hypercreatininemia.
Symptoms associated with impaired water-electrolyte balance – nausea, vomiting, pronounced decrease in blood pressure, dizziness, convulsions, drowsiness, confusion, polyuria or oliguria, anuria lead (due to hypovolemia).
Treatment: gastric lavage, appointment of activated charcoal, followed by reduction of water-electrolyte balance, symptomatic therapy. No specific antidote.
pharmachologic effect
Pharmacological group:
Indapamide relates to sulphonamide derivatives and pharmacological properties similar to the thiazide diuretics.
It has a moderate salureticheskim and diuretic effects, which are caused by inhibiting the reabsorption of sodium ions, and chlorine to a lesser extent of potassium and magnesium ions in the proximal renal tubule and cortical segment in the distal tubule of the nephron.
Indapamide reduces the tonus of smooth muscles of the arteries and exerts vasodilating action decreases total peripheral vascular resistance. These effects are mediated decrease in vascular reactivity to norepinephrine and angiotensin II; increase synthesis of prostaglandin E2 having vasodilating activity; inhibition of calcium current in vascular smooth muscle cells.
Indapamide reduces hypertrophy of the left ventricle of the heart. It has antihypertensive activity at doses that do not have a pronounced diuretic effect. At therapeutic doses, has no effect on lipid and carbohydrate metabolism (including patients with concomitant diabetes).
At regular reception therapeutic effect of indapamide develops within 1-2 weeks, reaches a maximum of 8-12 weeks and lasts up to 8 weeks. After a single dose maximum effect after 24 hours.
Indapamide after ingestion rapidly and completely absorbed in the gastrointestinal tract (bioavailability is high – 93%). Eating slows down the absorption rate of indapamide, but does not affect the absorption of completeness. Communication with plasma proteins – 71-79%. Also binds with elastin smooth muscles of the vascular wall. Has a high volume of distribution, it passes through the blood-tissue barriers (including placental). The time to reach maximum blood concentration is 1-2 hours. Indapamide is metabolized in the liver to inactive metabolites (about 5-7% of the dose of the drug excreted by the kidneys in unchanged form). Indapamide half-life averages 16 hours. The drug is excreted by the kidneys 60-80% in the form of metabolites through the intestine 20-23%. In patients with renal insufficiency, the pharmacokinetic parameters remain unchanged drug. Not accumulates.
Pregnancy and breast-feeding
Admission indapamide during pregnancy is not recommended. Use of the drug can cause placental ischemia with the risk of fetal growth retardation. If necessary, use during lactation should stop breastfeeding.
Conditions of supply of pharmacies
side effects
Classification of the incidence of side effects according to the recommendations of the World Health Organization: very common (> 1/10), common (by> 1/100 to
special instructions
During therapy with indapamide should regularly monitor the blood concentration of sodium ions, magnesium (as they can develop electrolyte disturbances), glucose, uric acid and residual nitrogen, blood pH level.
Patients taking the drug on a background Indapamide cardiac glycosides, laxatives, patients with hyperaldosteronism, as well as the elderly shows careful control of potassium ions and creatinine in the blood.
The first measurement of potassium ion concentration in the blood should be carried out during the first week of treatment.
The most careful control indicated for patients with liver cirrhosis (especially with edema or ascites) due to the risk of developing metabolic alkalosis, deteriorating during hepatic encephalopathy; with coronary artery disease, congestive heart failure, as well as elderly patients. High-risk group also includes patients with prolongation of the QT interval on the electrocardiogram (congenital or develop on the background of a pathological process). Hypercalcemia in patients receiving Indapamide drug may be a consequence of previously undiagnosed hyperparathyroidism.
Some patients may benefit from combination indapamiada with potassium-sparing diuretics, but it does not exclude the possibility of the development of hypo- or hyperkalemia, especially in patients with diabetes and renal failure.
In patients with diabetes should monitor blood glucose concentration, especially in the presence of hypokalemia.
Considerable dehydration during therapy Indapamide drug can lead to acute renal failure (due to a decrease in glomerular filtration rate). Patients need to be compensated BCC at the beginning of treatment and carefully monitor renal function.
Sulfonamide derivative can exacerbate during systemic lupus erythematosus (to be considered in the appointment of the drug indapamide).
Indapamide may give positive results in the conduct of the doping control.
Efficacy and safety in children under 18 years of age has not been established.
In patients receiving thiazide and thiazide diuretics reported cases of photosensitivity reactions (see. Section “Side effects”). In the case of photosensitivity reactions in patients receiving the drug should be discontinued treatment. If necessary, continue the diuretic therapy is recommended to protect the skin from exposure to sunlight or artificial UV rays.
Effects on ability to drive vehicles and management mechanisms
Early treatment with indapamide should refrain from driving motor vehicles and activities potentially hazardous activities that require high concentration and psychomotor speed reactions, as may develop dizziness.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Appointed inwardly independently of the meal, preferably in the morning. Indapamide drug should be taken, without chewing, drinking plenty of fluids.
When hypertension Indapamide drug is given in a dose – 2.5 mg 1 time per day. Increasing the dose does not lead to increased antihypertensive effect.
If after 4-8 weeks of treatment, desired therapeutic effect, the dose of the drug is not recommended to increase can not be achieved (risk of side effects without increasing the antihypertensive effect increases). Instead, the treatment regimen is recommended to include another antihypertensive agent that is not a diuretic. In the case of beginning treatment with two dose indapamide antihypertensives drug remains at 2.5 mg once daily in the morning.
In the treatment of elderly patients, the threshold concentration of creatinine in the blood plasma varies depending on age, weight and gender. Elderly patients to use the drug may Indapamide only normal kidney function, or with minor renal dysfunction.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review